COST-EFFECTIVENESS ANALYSIS OF PANITUMUMAB PLUS MFOLFOX6 VERSUS BEVACIZUMAB PLUS MFOLFOX6 FOR FIRST-LINE TREATMENT OF PATIENTS WITH WILD-TYPE RAS METASTATIC COLORECTAL CANCER

被引：0
|
作者：
Graham, C. N. [1 ]
Hechmati, G. [2 ]
Hjelmgren, J. [2 ]
De Liege, F. [3 ]
Lanier, J. [3 ]
Knoof, A. [3 ]
Knox, H. [1 ]
Barber, B. [4 ]
de Pouvourville, G. [5 ]
机构：
[1] RTI Hlth Solut, Res Triangle Pk, NC USA
[2] Amgen Europe GmbH, Zug, Switzerland
[3] Amgen France SAS, Neuilly Sur Seine, France
[4] Amgen Inc, Thousand Oaks, CA 91320 USA
[5] ESSEC Business Sch, Cergy Pontoise, France
来源：
VALUE IN HEALTH | 2014年 / 17卷 / 07期
关键词：
D O I：
10.1016/j.jval.2014.08.2264
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN106
引用
收藏
页码：A632 / A632
页数：1
相关论文
共 50 条
  • [1] Cost-effectiveness analysis of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 for first-line treatment of patients with wild-type RAS metastatic colorectal cancer
    Graham, Christopher N.
    Hechmati, Guy
    Hjelmgren, Jonas
    de Liege, Frederique
    Lanier, Julie
    Knox, Hediyyih
    Barber, Beth
    EUROPEAN JOURNAL OF CANCER, 2014, 50 (16) : 2791 - 2801
  • [2] Cost-effectiveness analysis in the Spanish setting of the PEAK trial of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 for first-line treatment of patients with wild-type RAS metastatic colorectal cancer
    Rivera, Fernando
    Valladares, Manuel
    Gea, Salvador
    Lopez-Martinez, Noemi
    JOURNAL OF MEDICAL ECONOMICS, 2017, 20 (06) : 574 - 584
  • [3] A randomized study of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 as first-line treatment for unresectable metastatic colorectal cancer
    Belhadef, S.
    Arab, A.
    Belmadi, M.
    Beninal, M.
    Bacha, N.
    Abdallah, R.
    Mechta, K.
    Dahmane, A.
    Mahfouf, H.
    Oukkal, M.
    Bouzid, K.
    Faraqun, S.
    Bentabak, K.
    Younes, S. Ait
    ANNALS OF ONCOLOGY, 2020, 31 : S92 - S92
  • [4] COST-EFFECTIVENESS ANALYSIS OF PANITUMUMAB plus MFOLFOX OVER BEVACIZUMAB plus MFOLFOX AS A FIRST-LINE TREATMENT FOR METASTATIC COLORECTAL CANCER PATIENTS WITH WILD-TYPE RAS IN GREECE
    Kourlaba, G.
    Boukovinas, I
    Saridaki, Z.
    Papagiannopoulou, V
    Tritaki, G.
    Maniadakis, N.
    VALUE IN HEALTH, 2014, 17 (07) : A633 - A633
  • [5] Panitumumab (PAN) plus mFOLFOX6 versus bevacizumab (BEV) plus mFOLFOX6 as first-line treatment in patients with RAS wild-type (metastatic colorectal cancer (mCRC): Results from the phase 3 PARADIGM trial.
    Yoshino, Takayuki
    Watanabe, Jun
    Shitara, Kohei
    Yasui, Hirofumi
    Ohori, Hisatsugu
    Shiozawa, Manabu
    Yamazaki, Kentaro
    Oki, Eiji
    Sato, Takeo
    Naitoh, Takeshi
    Komatsu, Yoshito
    Kato, Takeshi
    Hihara, Masamitsu
    Soeda, Junpei
    Yamamoto, Kouji
    Akagi, Kiwamu
    Ochiai, Atsushi
    Uetake, Hiroyuki
    Tsuchihara, Katsuya
    Muro, Kei
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (17)
  • [6] First-line panitumumab versus bevacizumab in combination with mFOLFOX6 for RAS wild-type metastatic colorectal cancer: PARADIGM trial results
    Muro, K.
    Watanabe, J.
    Shitara, K.
    Yamazaki, K.
    Ohori, H.
    Shiozawa, M.
    Yasui, H.
    Oki, E.
    Sato, T.
    Naitoh, T.
    Komatsu, Y.
    Kato, T.
    Hihara, M.
    Soeda, J.
    Yamamoto, K.
    Akagi, K.
    Ochiai, A.
    Uetake, H.
    Yoshino, T.
    ANNALS OF ONCOLOGY, 2022, 33 : S377 - S377
  • [7] A phase I/II, open-label, randomised study of nintedanib plus mFOLFOX6 versus bevacizumab plus mFOLFOX6 in first-line metastatic colorectal cancer patients
    Van Cutsem, E.
    Prenen, H.
    D'Haens, G.
    Bennouna, J.
    Carrato, A.
    Ducreux, M.
    Bouche, O.
    Sobrero, A.
    Latini, L.
    Staines, H.
    Oum'Hamed, Z.
    Dressler, H.
    Studeny, M.
    Capdevila, J.
    ANNALS OF ONCOLOGY, 2015, 26 (10) : 2085 - 2091
  • [8] Randomised phase II trial of mFOLFOX6 plus bevacizumab versus mFOLFOX6 plus cetuximab as first-line treatment for colorectal liver metastasis (ATOM trial)
    Eiji Oki
    Yasunori Emi
    Takeharu Yamanaka
    Hiroyuki Uetake
    Kei Muro
    Takao Takahashi
    Takeshi Nagasaka
    Etsuro Hatano
    Hitoshi Ojima
    Dai Manaka
    Tetsuya Kusumoto
    Yu Katayose
    Toshiyoshi Fujiwara
    Kazuhiro Yoshida
    Michiaki Unno
    Ichinosuke Hyodo
    Naohiro Tomita
    Kenichi Sugihara
    Yoshihiko Maehara
    British Journal of Cancer, 2019, 121 : 222 - 229
  • [9] PARADIGM study: A multicenter, randomized, phase III study of mFOLFOX6 plus panitumumab or bevacizumab as first-line treatment in patients with RAS (KRAS/NRAS) wild-type metastatic colorectal cancer
    Yoshino, Takayuki
    Uetake, Hiroyuki
    Tsuchihara, Katsuya
    Shitara, Kohei
    Yamazaki, Kentaro
    Watanabe, Jun
    Oki, Eiji
    Sato, Takeo
    Naitoh, Takeshi
    Komatsu, Yoshito
    Kato, Takeshi
    Mori, Ikuo
    Yamanaka, Kazunori
    Hihara, Masamitsu
    Soeda, Junpei
    Yamanaka, Takeharu
    Akagi, Kiwamu
    Ochiai, Atsushi
    Muro, Kei
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [10] PARADIGM study: A multicenter, randomized, phase III study of mFOLFOX6 plus panitumumab or bevacizumab as first-line treatment in patients with RAS (KRAS/NRAS) wild-type metastatic colorectal cancer
    Muro, Kei
    Uetake, Hiroyuki
    Tsuchihara, Katsuya
    Shitara, Kohei
    Yamazaki, Kentaro
    Oki, Eiji
    Sato, Takeo
    Naitoh, Takeshi
    Komatsu, Yoshito
    Kato, Takeshi
    Iwasaki, Kouji
    Soeda, Junpei
    Hihara, Masamitsu
    Yamanaka, Takeharu
    Ochiai, Atsushi
    Yoshino, Takayuki
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
12345